W omen living through midlife will experience menopause. Although menopause differs for each woman, approximately 80% of women will experience hot flashes and night sweats, with approximately 20% finding the symptoms so troublesome that they will seek treatment (Grady, 2006) . The rate of bone mass loss in women also accelerates to approximately 2% per year during menopause, leading to a higher risk of osteoporosis and fractures later in life (Ahlborg et al., 2001) .
Estrogen therapy reduces the frequency of hot flashes and night sweats by 60% to 95%, depending on dosage. Additionally, estrogen therapy decreases menopause-associated bone loss and lowers the risk of osteoporotic fractures (Ahlborg et al., 2001) . However, estrogen therapy can potentially increase the risk of stroke, venous thromboembolic events, and cognitive impairment (Anderson et al., 2004; Shumaker et al., 2004) . When progestin is added to estrogen therapy to prevent uterine hyperplasia and cancers associated with unopposed estrogen, the risk of stroke, venous thromboern- 01602-2597. E-mail: stephanie.chalupka@worcester.edu. doi:10.3928108910162-20111025-04 bolisrn, coronary events, breast cancer, and dementia increases (Rossouw et al., 2002; Shumaker et al., 2003) .
Because of the risks associated with hormone replacement therapy, many women are seeking alternatives such as soy-derived products to treat menopausal symptoms and prevent osteoporosis. However, study findings have been mixed regarding this alternative (Grady, 2006) .
Researchers designed the National Institutes of Health-funded Soy Phytoestrogens as Replacement Estrogens (SPARE) study to overcome the limitations of many prior trials of soy products, such as short duration, small sample size, and poor design (Grady, 2006) . The SPARE study enrolled 248 women (mean age, 52 years) in a single-center, randomized, placebo-controlled, double-blind clinical trial conducted from July 1,2004 , through March 31, 2009 Non-osteoporotic women with the onset of menopause within 5 years of enrollment were randomly assigned to receive either daily soy isoflavones (200 mg) or placebo for 2 years. Outcomes including spine and hip bone-mineral density (BMD), menopausal symptoms, and vaginal epithelial maturation were assessed at baseline and at 12 and 24 months.
At baseline measurement, more than two thirds of the participants reported more than one symptom of menopause, and vaginal maturation was consistent with hypoestrogenism in both groups. After 2 years, BMD had declined by approximately 2% in both groups. Additionally, almost half (48%) of the women in the soy group, but only 32% in the placebo group, reported experiencing hot flashes (p = .02). Vaginal epithelial maturation did not change significantly from baseline in either group. Rates of adverse events were generally similar in the two groups. However, constipation was reported by 31% and 21% of the women in the soy group and the placebo group, respectively.
